Log in

Relevant bibliographies by topics / Human Leukocyte Antigen-G / Journal articles

Journal articles on the topic 'Human Leukocyte Antigen-G'

To see the other types of publications on this topic, follow the link: Human Leukocyte Antigen-G.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Human Leukocyte Antigen-G.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Curigliano, Giuseppe, Carmen Criscitiello, Lucia Gelao, and Aron Goldhirsch. "Molecular Pathways: Human Leukocyte Antigen G (HLA-G)." Clinical Cancer Research 19, no. 20 (July 29, 2013): 5564–71. http://dx.doi.org/10.1158/1078-0432.ccr-12-3697.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sun, Juan, Yan-Xiang Chang, and Chun-Yan Niu. "Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites." Tumor Biology 39, no. 11 (November 2017): 101042831772684. http://dx.doi.org/10.1177/1010428317726840.

Full text

Abstract:

The overexpression of soluble human leukocyte antigen-G is associated with malignant tumours. The purpose of our study was to detect soluble human leukocyte antigen-G concentrations in ascites and to evaluate the value of ascitic soluble human leukocyte antigen-G for the diagnosis of malignant ascites. Enzyme-linked immunosorbent assay was used to detect soluble human leukocyte antigen-G levels in 64 patients with malignant ascites and 30 patients with benign ascites. Receiver operating characteristic curves were used to evaluate the diagnostic efficacy of ascitic soluble human leukocyte antigen-G for the detection of malignant ascites. Ascitic soluble human leukocyte antigen-G levels were significantly higher in the malignant ascites group than in the benign ascites group (20.718 ± 3.215 versus 12.467 ± 3.678 µg/L, t = 7.425, p < 0.001). The area under the receiver operating characteristic curve for ascitic soluble human leukocyte antigen-G was 0.957 (95% confidence interval, 0.872–0.992). At a cut-off value of 19.60 µg/L, the sensitivity and specificity of ascitic soluble human leukocyte antigen-G were 87.5% (95% confidence interval, 71.0%–96.5%) and 100% (95% confidence interval, 88.4%–100%), respectively. With respect to area under the receiver operating characteristic curve, sensitivity and specificity, ascitic carcinoembryonic antigen (0.810, 68.75% and 83.33%, respectively) and carbohydrate antigen 19-9 (0.710, 65.63% and 70%, respectively) significantly differed (all p < 0.05). In malignant ascites that were cytology-negative and biopsy-positive, the rate of positivity for ascitic soluble human leukocyte antigen-G was 75%, which was higher than the corresponding rates for ascitic carcinoembryonic antigen (31.25%) and carbohydrate antigen 19-9 (6.25%; both p < 0.05). In conclusion, The detection of ascitic soluble human leukocyte antigen-G exhibited good performance for diagnosing malignant ascites, and particularly those that were cytology-negative and biopsy-positive.

APA, Harvard, Vancouver, ISO, and other styles

3

Mattuella, Letícia Grando, Lisiane Bernardi, Francis Maria Báo Zambra, Milene Borges Campagnaro, Rui Vicente Oppermann, Léder Leal Xavier, José Artur Bogo Chies, and Letícia Algarves Miranda. "Human leukocyte antigen-G polymorphisms in periodontitis." Acta Odontologica Scandinavica 78, no. 2 (September 13, 2019): 141–45. http://dx.doi.org/10.1080/00016357.2019.1662942.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Yanqing, Meimei Lai, Yunyan Lou, Qiuyue Han, Qing Yang, Minguang Chen, Jingbo Li, Huiyan Wang, Weihua Yan, and Xiaoqun Zheng. "Elevation of plasma-soluble HLA-G in childhood nephrotic syndrome is associated with IgE." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 54, no. 1 (September 28, 2016): 69–75. http://dx.doi.org/10.1177/0004563216637625.

Full text

Abstract:

Background Nephrotic syndrome is related to immune system dysfunction. Soluble human leukocyte antigen-G has been suggested to have an immunomodulatory role. Additionally, human leukocyte antigen-G expression may be influenced by the 14-base pair insertion/deletion polymorphism. However, this molecule has not been investigated in nephrotic syndrome. Methods Fifty-five children with nephrotic syndrome were enrolled: 24 primary nephrotic syndrome patients and 31 recurrent nephrotic syndrome patients. A group of 120 healthy subjects were included as reference controls. Additionally, 22 patients in nephrotic syndrome remission after treatments were also included. Both nephrotic syndrome patients and healthy subjects were genotyped for the 14-base pair insertion/deletion polymorphism. Plasma soluble human leukocyte antigen-G concentrations and serum immunoglobulin concentrations were determined. Results Nephrotic syndrome patients showed significantly higher levels of both soluble human leukocyte antigen-G and immunoglobulin E compared to normal controls. Nephrotic syndrome patients presented a higher frequency of the −14-base pair allele than did normal controls. Soluble human leukocyte antigen-G concentrations in remission patients were dramatically lower compared to in nephrotic syndrome patients. Moreover, soluble human leukocyte antigen-G and immunoglobulin E were moderately correlated in nephrotic syndrome patients. Conclusions The present study demonstrated that plasma soluble human leukocyte antigen-G concentrations were significantly elevated and that a relationship between serum total immunoglobulin E in nephrotic syndrome patients and the human leukocyte antigen-G −14-base pair allele may be a risk factor for nephrotic syndrome. These findings suggest that soluble human leukocyte antigen-G may be used as a monitoring marker for nephrotic syndrome patients' condition.

APA, Harvard, Vancouver, ISO, and other styles

5

Mittal, Balraj. "Yoga, rheumatoid arthritis & human leukocyte antigen-G." Indian Journal of Medical Research 155, no. 2 (2022): 225. http://dx.doi.org/10.4103/ijmr.ijmr_785_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Matte, Claudine, Lynn S. Zijenah, Julie Lacaille, Brian Ward, and Michel Roger. "Mother-to-child human leukocyte antigen G concordance." AIDS 16, no. 18 (December 2002): 2491–94. http://dx.doi.org/10.1097/00002030-200212060-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Fuiii, T. "Structure and function of human leukocyte antigen-G." Placenta 19, no. 7 (September 1998): A15. http://dx.doi.org/10.1016/s0143-4004(98)91101-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Warner, Carol M., Paula W. Lampton, Judith A. Newmark, and Jacques Cohen. "Soluble human leukocyte antigen-G and pregnancy success." Reproductive BioMedicine Online 17, no. 4 (January 2008): 470–85. http://dx.doi.org/10.1016/s1472-6483(10)60233-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Clark, David A. "Human Leukocyte Antigen-G: New Roles for Old?" American Journal of Reproductive Immunology 41, no. 2 (February 1999): 117–20. http://dx.doi.org/10.1111/j.1600-0897.1999.tb00085.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Zarkhin, Valeriya, Maria Bezchinsky, Li Li, and Minnie M. Sarwal. "Soluble Human Leukocyte Antigen-G in Pediatric Renal Transplantation." Transplantation 92, no. 1 (July 2011): e1-e2. http://dx.doi.org/10.1097/tp.0b013e31821d91a1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Urosevic, Mirjana, and Reinhard Dummer. "Human Leukocyte Antigen–G and Cancer Immunoediting: Figure 1." Cancer Research 68, no. 3 (February 1, 2008): 627–30. http://dx.doi.org/10.1158/0008-5472.can-07-2704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

YAN, Wei-hua, and Ai-fen LIN. "Current opinion on human leukocyte antigen-G in China." Chinese Medical Journal 120, no. 14 (July 2007): 1260–65. http://dx.doi.org/10.1097/00029330-200707020-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Rebmann, Vera, Diana Bartsch, Andreas Wunsch, Petra Möllenbeck, Thomas Golda, Richard Viebahn, and Hans Grosse-Wilde. "Soluble total human leukocyte antigen class I and human leukocyte antigen–G molecules in kidney and kidney/pancreas transplantation." Human Immunology 70, no. 12 (December 2009): 995–99. http://dx.doi.org/10.1016/j.humimm.2009.07.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

AKIN, Murat, Latife Arzu ARAL, Aydın YAVUZ, Harun KARABACAK, Kürşat DİKMEN, and Hasan BOSTANCI. "Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer." TURKISH JOURNAL OF MEDICAL SCIENCES 47 (2017): 1263–66. http://dx.doi.org/10.3906/sag-1611-25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Barrier, Breton F., Brian S. Kendall, Kathy L. Sharpe-Timms, and Edward R. Kost. "Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma." Gynecologic Oncology 103, no. 1 (October 2006): 25–30. http://dx.doi.org/10.1016/j.ygyno.2006.01.045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Feng, Qi, Ji Ma, Xin Li, Ming Hou, and Jun Peng. "Human Leukocyte Antigen-G Restores Immune Tolerance in Immune Thrombocytopenia." Blood 132, Supplement 1 (November 29, 2018): 3751. http://dx.doi.org/10.1182/blood-2018-99-115713.

Full text

Abstract:

Abstract Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder in which loss of immune tolerance leads to platelet destruction. Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I antigen including four membrane-bound (mHLA-G, HLA-G1 to -G4) and three soluble (sHLA-G, HLA-G5 to -G7) isoforms due to alternative splicing of the HLA-G primary transcript. HLA-G exerts immunosuppressive functions by interacting with its inhibitory receptors, immunoglobulin-like transcripts (ILTs), expressing differentially on natural killer cells, T cells, and antigen presenting cells. Upon binding to ILTs, HLA-G suppressed lymphocyte proliferation, promoted apoptosis of cytotoxic lymphocytes and natural killer cells, inhibited antibody secretion from activated B cells, and induced expansion of suppressive T cells, tolerogenic dendritic cells and myeloid-derived suppressor cells. HLA-G supports immune escape, and high level of HLA-G is associated with unfavorable outcomes in cancer patients. Meanwhile, HLA-G-induced tolerance can benefit human allotransplantation and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, but the role of HLA-G in the treatment of ITP is still unclear. Here we observed significantly less soluble HLA-G in plasma from ITP patients positive for anti-glycoprotein (GP) IIb/IIIa and/or anti-GPIb/IX autoantibodies compared with autoantibody-negative patients or healthy controls. However, no significant difference was found in the sHLA-G levels between anti-glycoprotein (GP) IIbIIIa and anti-GPIb-IX autoantibodies groups. Interestingly, sHLA-G is positively correlated with platelet counts in ITP patients both with and without autoantibodies, suggesting that HLA-G can also protect platelets from destruction through other mechanisms. To elucidate this, we then analyzed both expression of membrane HLA-G and ILTs on PBMCs. Our data found less membrane-bound HLA-G and ILTs on CD4+T cells and CD14+cells in ITP patients. Moreover, recombinant human HLA-G (rhHLA-G) upregulated expression of ILT2 on CD4+and ILT4 on CD14+cells. The upregulation of ILT by rhHLA-G indicates that sHLA-G might also benefit ITP patients negative for anti-platelet autoantibodies. To determine whether rhHLA-G affects T cell differentiation, we tested 17 cytokines by ELISA to investigate the immune environment with or without rhHLA-G, and found that rhHLA-G upregulated Interleukin (IL)-4 and IL-10, and downregulated tumor necrosis factor-α, IL-12, and IL-17 secreted by ITP patient peripheral blood mononuclear cells (PBMCs), indicating a promotion of helper T(Th)2 and inhibition of Th1 and Th17 differentiation. However, our results indicated that rhHLA-G did not expand the CD4+CD25+Foxp3+regulatory T cells(Tregs). In addition, rhHLA-G exerted their immunosuppressive effects by upregulating IL-1β, IL-2, Granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony stimulating factor (GM-CSF). By reprogramming the cytokine profile in ITP patients, HLA-G established an optimal environment for the impaired cell populations, such as dendritic cells (DCs), to regain their tolerogenic function. Our results showed that rhHLA-G inhibited monocyte-derived DCs maturation by downregulating CD80 and CD86 expression. To further assess whether the rhHLA-G modulated-DCs were functionally tolerogenic, PBMCs were then cocultured with rhHLA-G modulated-DCs. Our results showed that rhHLA-G-modulated DCs from ITP patients suppressed CD4+T cell proliferation by 38.8% compared to unmodulated cells. Besides, PBMCs exposed to rhHLA-G were less cytotoxic toward plateletsfrom ITP patients or healthy subjects. This study provides a potential strategy to protect exogenous platelets from destruction in ITP patients. In conclusion, our data demonstrated that impaired expression of HLA-G and/or ILT is involved in the pathogenesis of ITP, and recombinant human HLA-G can restore immune tolerance in ITP patients via upregulation of ILTs, which indicates that HLA-G can be a diagnostic marker and also a therapeutic option for ITP treatment. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

17

Tahan, Fulya, and Turkan Patıroglu. "Plasma Soluble Human Leukocyte Antigen G Levels in Asthmatic Children." International Archives of Allergy and Immunology 141, no. 3 (2006): 213–16. http://dx.doi.org/10.1159/000095290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Yan, Wei-Hua. "Human leukocyte antigen-G in cancer: Are they clinically relevant?" Cancer Letters 311, no. 2 (December 2011): 123–30. http://dx.doi.org/10.1016/j.canlet.2011.07.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rosado, Silvia, Gema Perez-Chacon, Susana Mellor-Pita, Inmaculada Sanchez-Vegazo, Carmen Bellas-Menendez, Maria Jesus Citores, Ignacio Losada-Fernandez, Trinidad Martin-Donaire, Nerea Rebolleda, and Paloma Perez-Aciego. "Expression of human leukocyte antigen-G in systemic lupus erythematosus." Human Immunology 69, no. 1 (January 2008): 9–15. http://dx.doi.org/10.1016/j.humimm.2007.11.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Schütt, Philipp, Birgit Schütt, Magdalena Switala, Sebastian Bauer, Georgios Stamatis, Bertram Opalka, Wilfried Eberhardt, Martin Schuler, Peter A. Horn, and Vera Rebmann. "Prognostic relevance of soluble human leukocyte antigen–G and total human leukocyte antigen class I molecules in lung cancer patients." Human Immunology 71, no. 5 (May 2010): 489–95. http://dx.doi.org/10.1016/j.humimm.2010.02.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Copeman, James, Robin N. N. Han, Isabella Caniggia, Michael McMaster, Susan J. Fisher, and James C. Cross. "Posttranscriptional Regulation of Human Leukocyte Antigen G During Human Extravillous Cytotrophoblast Differentiation1." Biology of Reproduction 62, no. 6 (June 1, 2000): 1543–50. http://dx.doi.org/10.1095/biolreprod62.6.1543.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Mociornita, A. G., L. C. Tumiati, P. C. Papageorgiou, L. Grosman, A. Ghashghai, H. J. Ross, R. K. Li, D. H. Delgado, and V. Rao. "Human Leukocyte Antigen-G Inhibits Human Coronary Artery Smooth Muscle Cell Proliferation." Journal of Heart and Lung Transplantation 32, no. 4 (April 2013): S298. http://dx.doi.org/10.1016/j.healun.2013.01.848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Teixeira, A. C., M. Brunaldi, J. C. O. Crispim, E. A. Donadi, and A. L. C. Martinelli. "659 HIGH HUMAN LEUKOCYTE ANTIGEN G (HLA-G) EXPRESSION IN HEPATOCELLULAR CARCINOMA (HCC)." Journal of Hepatology 58 (April 2013): S268. http://dx.doi.org/10.1016/s0168-8278(13)60661-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Jeong, Seri, Seho Park, Byeong-Woo Park, Younhee Park, Oh-Joong Kwon, and Hyon-Suk Kim. "Human Leukocyte Antigen-G (HLA-G) Polymorphism and Expression in Breast Cancer Patients." PLoS ONE 9, no. 5 (May 28, 2014): e98284. http://dx.doi.org/10.1371/journal.pone.0098284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Prakash, Swayam, Maneesh Kumar Misra, and Suraksha Agrawal. "Non-Classical Human Leukocyte Antigen-G Allelic Diversity Among North Indians." Anthropology - Open Journal 2, no. 1 (March 15, 2017): 1–9. http://dx.doi.org/10.17140/antpoj-2-106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Elliott, Robert L., Xian P. Jiang, Jeffrey T. Phillips, Brian G. Barnett, and Jonathan F. Head. "Human Leukocyte Antigen G Expression in Breast Cancer: Role in Immunosuppression." Cancer Biotherapy and Radiopharmaceuticals 26, no. 2 (April 2011): 153–57. http://dx.doi.org/10.1089/cbr.2010.0924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Malagutti, Nicola, Claudia Aimoni, Alessandra Balboni, Marina Stignani, Loredana Melchiorri, Michela Borin, Antonio Pastore, Roberta Rizzo, and Olavio Roberto Baricordi. "Decreased Production of Human Leukocyte Antigen G Molecules in Sinonasal Polyposis." American Journal of Rhinology 22, no. 5 (September 2008): 468–73. http://dx.doi.org/10.2500/ajr.2008.22.3210.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Park, Y., Y. Park, Y. S. Kim, O. J. Kwon, and H. S. Kim. "Allele frequencies of human leukocyte antigen-G in a Korean population." International Journal of Immunogenetics 39, no. 1 (October 29, 2011): 39–45. http://dx.doi.org/10.1111/j.1744-313x.2011.01053.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Goldman-Wohl, Debra, Ilana Ariel, Caryn Greenfield, Drorit Hochner-Celnikier, Yuval Lavy, and Simcha Yagel. "A study of human leukocyte antigen G expression in hydatidiform moles." American Journal of Obstetrics and Gynecology 185, no. 2 (August 2001): 476–80. http://dx.doi.org/10.1067/mob.2001.115994.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Khalil-Daher, Iman, Nathalie Rouas-Freiss, Edgardo D. Carosella, and Jean B. Dausset. "Human Leukocyte Antigen-G: Immunotolerant Major Histocompatibility Complex Molecule in Transplantation." World Journal of Surgery 24, no. 7 (July 2000): 819–22. http://dx.doi.org/10.1007/s002680010131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Fregonezi, Paula A. G., Tarsia G. A. Silva, Renata T. Simões, Philipe Moreau, Edgardo D. Carosella, Carla P. M. Kläy, Maria A. G. Gonçalves, et al. "Expression of nonclassical molecule human leukocyte antigen–G in oral lesions." American Journal of Otolaryngology 33, no. 2 (March 2012): 193–98. http://dx.doi.org/10.1016/j.amjoto.2010.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tahan, Fulya, Hatice Eke Gungor, Himmet Haluk Akar, and Berkay Saraymen. "Increased plasma soluble human leukocyte antigen‐G in persistent wheezy infants." Pediatrics International 59, no. 5 (May 2017): 530–33. http://dx.doi.org/10.1111/ped.13207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lazarte, Julieta, Livia Goldraich, Cedric Manlhiot, Stella Kozuszko, Vivek Rao, and Diego Delgado. "Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation." Human Immunology 77, no. 9 (September 2016): 805–11. http://dx.doi.org/10.1016/j.humimm.2016.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Pan, Ying-qiu, Yan-yun Ruan, Jin-bang Peng, Qiu-Yue Han, Xia Zhang, Aifen Lin, and Wei-hua Yan. "Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer." Human Immunology 77, no. 4 (April 2016): 317–24. http://dx.doi.org/10.1016/j.humimm.2016.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Mociornita, A. G., L. Tumiati, L. Grosman-Rimon, H. J. Ross, R. Li, D. H. Delgado, and V. Rao. "379 Human Leukocyte Antigen-G Inhibits Human Coronary Artery Smooth Muscle Cell Proliferation." Canadian Journal of Cardiology 28, no. 5 (September 2012): S240—S241. http://dx.doi.org/10.1016/j.cjca.2012.07.357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Shih, Ie-Ming. "Application of Human Leukocyte Antigen–G Expression in the Diagnosis of Human Cancer." Human Immunology 68, no. 4 (April 2007): 272–76. http://dx.doi.org/10.1016/j.humimm.2007.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Rizzo, Roberta, Marina Stignani, Loredana Melchiorri, and Olavio R. Baricordi. "Possible role of human leukocyte antigen–G molecules in human oocyte/embryo secretome." Human Immunology 70, no. 12 (December 2009): 970–75. http://dx.doi.org/10.1016/j.humimm.2009.07.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Yie, S. M., L. H. Li, J. Cross, and C. L. Librach. "Human Leukocyte Antigen G (HLA-G) Gene Expression is Regulated by Progesterone In Vitro." Fertility and Sterility 74, no. 3 (September 2000): S9. http://dx.doi.org/10.1016/s0015-0282(00)00748-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gonzalez, Álvaro, Estibaliz Alegre, Ainhoa Arroyo, Jöel LeMaoult, and José Ignacio Echeveste. "Identification of Circulating Nonclassic Human Leukocyte Antigen G (HLA-G)–Like Molecules in Exudates." Clinical Chemistry 57, no. 7 (July 1, 2011): 1013–22. http://dx.doi.org/10.1373/clinchem.2010.159673.

Full text

Abstract:

BACKGROUND HLA-G in biological fluids has been proposed to be useful as a tumor marker as both a diagnostic and prognostic factor. Most HLA-G measurement procedures are based on ELISA methods using highly specific antibodies. However, results of published studies are in conflict regarding the clinical utility and even the nature of HLA-G present in circulation. METHODS We collected 118 exudates, 94 from cancer patients and 24 from patients without tumors. We measured HLA-G concentrations by ELISA using MEM-G/9 or G233 as capture antibody. Samples were immunoprecipitated with an anti–HLA-G antibody and analyzed by Western blot using a different anti–HLA-G antibody. RESULTS Discrepancies in HLA-G concentrations in exudates were observed depending on what capture anti–HLA-G antibody was used for ELISA (r = 0.376). These discrepancies were not observed when the ELISAs were performed using culture supernatants from HLA-G1–transfected cells (r = 0.983). Immunoprecipitation and Western blot of cell culture supernatants with 2 different anti–HLA-G antibodies produced the typical band at 39 kDa assigned to HLA-G. When the immunoprecipitation and western blot were performed with exudates, however, there were bands at 53 kDa and 70–76 kDa, higher molecular weights than those usually assigned to HLA-G. These HLA-G–like molecules were associated with β2-microglobulin and could also form disulfide bridges with other HLA-G–like molecules. CONCLUSIONS The main HLA-G antigenic molecules in exudates are HLA-G–like complexes, a factor that should be considered when analyzing HLA-G in biological fluids.

APA, Harvard, Vancouver, ISO, and other styles

40

Avelino, Melissa Ameloti Gomes, Isabela Jubé Wastowski, Ricardo Gimenes Ferri, Thaís Gomes Abrahão Elias, Ana Paula Lindoso Lima, Larissa Cardoso Marinho, and Shirley Shizue Nagata Pignatari. "The human leukocyte antigen G molecule (HLA-G) expression in patients with nasal polyposis." Brazilian Journal of Otorhinolaryngology 80, no. 3 (May 2014): 208–12. http://dx.doi.org/10.1016/j.bjorl.2014.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Allo, Sarjani Linggi, Erni Yetti R, Zadrak Tombeg, Samrichard Rambulangi, Irfan Idris, and Anto J. Hadi. "Kadar Human Leukocyte Antigen-G Serum Pada Abortus Spontan Dan Kehamilan Normal." MPPKI (Media Publikasi Promosi Kesehatan Indonesia): The Indonesian Journal of Health Promotion 2, no. 2 (May 31, 2019): 116–21. http://dx.doi.org/10.31934/mppki.v2i2.567.

Full text

Abstract:

Adanya penolakan terhadap janin oleh sistim imun ibu karena adanya antigen paternal, diduga menjadi salah satu penyebab abortus oleh karena itu adanya humanleukocyte antigen-g (HLA-G) memegang peran toleransi imun semialogenik fetus untuk pemeliharaan kehamilan.Penelitian ini bertujuan untuk mengetahui kadar HLAG-G serum pada kehamilan normal dan Abortus dengan metode ELISA.Desain penelitian ini adalah cros-sectional dengan jumlah sampel 50 yang dibagi dalam 2 kelompok yaitu25 abortus dan 25 kehamilan normal. Pengambilan sampel dilakukan secara concequtivesampling.Data dianalisis menggunakan uji Mann-whitneydan Independent-samples T test. Hasil uji statistik diperoleh rerata kadar HLA-G serum ibu abortus lebih rendah (276,08 ±69 ng/L) dibandingkan dengan hamil normal (345,30 ± 73,54ng/L) dengan nilai p 0,001 <p 0,005. Pada usia ibu 20-35 tahun rerata kadar HLAG pada kehamilan normal 357,57 ± 71,40 dan kelompok abortus 274,57±85,95 dengan nilai = p 0,015 sedangkan pada usia ibu <20 dan >35 tahun rerata kadar HLA-G kehamilan normal 306,41±72,26 dan kelompok abortus 276,79±62,68 dengan nilai p=0,034. Umur kehamilan > 14 minggu pada kelompok hamil normal rerata kadar HLAG =353,43±78,17 dan kelompok abortus HLA-G = 243,60 +61,77 dengan nilaip =0,003 sedangkan umur kehamilan 8-14 minggu pada kelompok hamil normal rerata kada HLA-G= 328,01±63,82 dan pada kelompok abortus 288,71±69,22 dengan nilai p=0,185. Paritas 2-3 pada kelompok hamil normal rerata HLA-G=342,87±73,42 dan kelompok abortus rerata HLA-G= 278,35±81,25 dengan nilai p=0,051 sedangkan paritas 1&> 3 pada kelompok hamilan normal rerata kadar HLA-G =350,46±78,57 dan kelompok abortus rerata kadar HLA-G = 274,80 ±64,14 dengan nilai p 0,043. Berdasarkan hasil analisis disimpulkan bahwa kadar serum HLA-G pada kelompok abortus lebih rendah dibandingkan kelompok hamilan normal.

APA, Harvard, Vancouver, ISO, and other styles

42

Allo, Sarjani Linggi, Erni Yetti R, Zadrak Tombeg, Samrichard Rambulangi, Irfan Idris, and Anto J. Hadi. "Kadar Human Leukocyte Antigen-G Serum Pada Abortus Spontan Dan Kehamilan Normal." Media Publikasi Promosi Kesehatan Indonesia (MPPKI) 2, no. 2 (May 31, 2019): 116–21. http://dx.doi.org/10.56338/mppki.v2i2.567.

Full text

Abstract:

Adanya penolakan terhadap janin oleh sistim imun ibu karena adanya antigen paternal, diduga menjadi salah satu penyebab abortus oleh karena itu adanya humanleukocyte antigen-g (HLA-G) memegang peran toleransi imun semialogenik fetus untuk pemeliharaan kehamilan.Penelitian ini bertujuan untuk mengetahui kadar HLAG-G serum pada kehamilan normal dan Abortus dengan metode ELISA.Desain penelitian ini adalah cros-sectional dengan jumlah sampel 50 yang dibagi dalam 2 kelompok yaitu25 abortus dan 25 kehamilan normal. Pengambilan sampel dilakukan secara concequtivesampling.Data dianalisis menggunakan uji Mann-whitneydan Independent-samples T test. Hasil uji statistik diperoleh rerata kadar HLA-G serum ibu abortus lebih rendah (276,08 ±69 ng/L) dibandingkan dengan hamil normal (345,30 ± 73,54ng/L) dengan nilai p 0,001 <p 0,005. Pada usia ibu 20-35 tahun rerata kadar HLAG pada kehamilan normal 357,57 ± 71,40 dan kelompok abortus 274,57±85,95 dengan nilai = p 0,015 sedangkan pada usia ibu <20 dan >35 tahun rerata kadar HLA-G kehamilan normal 306,41±72,26 dan kelompok abortus 276,79±62,68 dengan nilai p=0,034. Umur kehamilan > 14 minggu pada kelompok hamil normal rerata kadar HLAG =353,43±78,17 dan kelompok abortus HLA-G = 243,60 +61,77 dengan nilaip =0,003 sedangkan umur kehamilan 8-14 minggu pada kelompok hamil normal rerata kada HLA-G= 328,01±63,82 dan pada kelompok abortus 288,71±69,22 dengan nilai p=0,185. Paritas 2-3 pada kelompok hamil normal rerata HLA-G=342,87±73,42 dan kelompok abortus rerata HLA-G= 278,35±81,25 dengan nilai p=0,051 sedangkan paritas 1&> 3 pada kelompok hamilan normal rerata kadar HLA-G =350,46±78,57 dan kelompok abortus rerata kadar HLA-G = 274,80 ±64,14 dengan nilai p 0,043. Berdasarkan hasil analisis disimpulkan bahwa kadar serum HLA-G pada kelompok abortus lebih rendah dibandingkan kelompok hamilan normal.

APA, Harvard, Vancouver, ISO, and other styles

43

LeMaoult, J., M. Le Discorde, N. Rouas-Freiss, P. Moreau, C. Menier, J. McCluskey, and E. D. Carosella. "Biology and functions of human leukocyte antigen-G in health and sickness*." Tissue Antigens 62, no. 4 (September 16, 2003): 273–84. http://dx.doi.org/10.1034/j.1399-0039.2003.00143.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

White, S. R., D. A. Loisel, J. F. McConville, R. Stern, Y. Tu, B. A. Marroquin, I. Noth, and C. Ober. "Levels of soluble human leukocyte antigen-G are increased in asthmatic airways." European Respiratory Journal 35, no. 4 (March 31, 2010): 925–27. http://dx.doi.org/10.1183/09031936.00164809.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tripathi, Piyush, and Suraksha Agrawal. "The role of human leukocyte antigen E and G in HIV infection." AIDS 21, no. 11 (July 2007): 1395–404. http://dx.doi.org/10.1097/qad.0b013e32810c8bbc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Lazarte, J., L. Goldraich, C. Manlhiot, V. Rao, and D. Delgado. "Post Heart Transplant Cancer Diagnosis Association with Human Leukocyte Antigen-G Genotypes." Journal of Heart and Lung Transplantation 35, no. 4 (April 2016): S207. http://dx.doi.org/10.1016/j.healun.2016.01.580.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lazarte, J., L. Goldraich, H. Kawajiri, A. Ghashghai, L. Grosman-Rimon, L. Tumiati, V. Rao, and D. Delgado. "Human Leukocyte Antigen-G Polymorphisms as Predictors of Early Cardiac Allograft Vasculopathy." Journal of Heart and Lung Transplantation 34, no. 4 (April 2015): S99. http://dx.doi.org/10.1016/j.healun.2015.01.264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Joseph, J. M., A. G. Mociornita, L. Tumiati, L. Grosman-Rimon, V. Rao, and D. H. Delgado. "295 Is soluble human-leukocyte Antigen-G immunoprotective in heart transplant recipients?" Canadian Journal of Cardiology 27, no. 5 (September 2011): S170. http://dx.doi.org/10.1016/j.cjca.2011.07.223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Fainardi, Enrico, Roberta Rizzo, Massimiliano Castellazzi, Marina Stignani, Enrico Granieri, and Olavio Roberto Baricordi. "Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis." Human Immunology 70, no. 12 (December 2009): 981–87. http://dx.doi.org/10.1016/j.humimm.2009.07.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Larsen, Margit Hørup, and Thomas Vauvert F. Hviid. "Human leukocyte antigen-G polymorphism in relation to expression, function, and disease." Human Immunology 70, no. 12 (December 2009): 1026–34. http://dx.doi.org/10.1016/j.humimm.2009.07.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!